^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
eramkafusp alfa (IGN002)
i
Other names: IGN002, IGN-002, IGN 002
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Assertio
Drug class:
CD20 inhibitor, IFNα stimulant
Related drugs:
over2years
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects (clinicaltrials.gov)
P1, N=62, Terminated, Spectrum Pharmaceuticals, Inc | Recruiting --> Terminated; Strategic Reasons
Trial termination
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
eramkafusp alfa (IGN002)
over3years
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects (clinicaltrials.gov)
P1, N=62, Recruiting, Spectrum Pharmaceuticals, Inc | Suspended --> Recruiting
Enrollment open
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
eramkafusp alfa (IGN002)
Share via
